The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell …

O Arrieta, AF Cardona, L Corrales, AD Campos-Parra… - Lung cancer, 2015 - Elsevier
Objectives In non-small cell lung cancer (NSCLC), the association between common EGFR
mutations (Del EX19/L858R) with EGFR tyrosine kinase inhibitors (EGFR-TKIs) has been …
被引用次数：98 相关文章

The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell …

O Arrieta, AF Cardona, L Corrales… - Lung …, 2015 - lungcancerjournal.info
Objectives In non-small cell lung cancer (NSCLC), the association between common EGFR
mutations (Del EX19/L858R) with EGFR tyrosine kinase inhibitors (EGFR-TKIs) has been …
[PDF] academia.edu

[PDF][PDF] The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small …

O Arrieta, AF Cardona, L Corrales, AD Campos-Parra… - Lung …, 2015 - academia.edu
abstract Objectives: In non-small cell lung cancer (NSCLC), the association between
common EGFR mutations (Del EX19/L858R) with EGFR tyrosine kinase inhibitors (EGFR …

[引用][C] The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small …

O Arrieta, AF Cardona, L Corrales, AD Campos-Parra… - Lung Cancer, 2015 - cir.nii.ac.jp
The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase
inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer | CiNii …

The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell …

O Arrieta, AF Cardona, L Corrales… - Lung Cancer …, 2014 - europepmc.org
Objectives In non-small cell lung cancer (NSCLC), the association between common EGFR
mutations (Del EX19/L858R) with EGFR tyrosine kinase inhibitors (EGFR-TKIs) has been …

The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell …

O Arrieta, AF Cardona, L Corrales, AD Campos-Parra… - Lung Cancer, 2015 - infona.pl
In non-small cell lung cancer (NSCLC), the association between common EGFR mutations
(Del EX19/L858R) with EGFR tyrosine kinase inhibitors (EGFR-TKIs) has been well …

The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell …

O Arrieta, AF Cardona, L Corrales… - Lung cancer …, 2015 - pubmed.ncbi.nlm.nih.gov
Objectives In non-small cell lung cancer (NSCLC), the association between common EGFR
mutations (Del EX19/L858R) with EGFR tyrosine kinase inhibitors (EGFR-TKIs) has been …